X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (111) 111
humans (109) 109
oncology (89) 89
child (81) 81
male (77) 77
female (76) 76
infant (75) 75
child, preschool (74) 74
adolescent (59) 59
neuroblastoma (47) 47
pediatrics (41) 41
cancer (38) 38
prognosis (33) 33
children (31) 31
chemotherapy (30) 30
hematology (29) 29
antineoplastic combined chemotherapy protocols - therapeutic use (28) 28
treatment outcome (25) 25
neuroblastoma - pathology (24) 24
adult (22) 22
combined modality therapy (21) 21
risk factors (21) 21
follow-up studies (20) 20
infant, newborn (20) 20
tumors (20) 20
neuroblastoma - genetics (18) 18
diagnosis (17) 17
neuroblastoma - drug therapy (17) 17
neuroblastoma - mortality (17) 17
retrospective studies (17) 17
neoplasm staging (16) 16
survival rate (16) 16
neuroblastoma - therapy (15) 15
surgery (15) 15
kaplan-meier estimate (14) 14
time factors (14) 14
age (13) 13
bone-marrow-transplantation (13) 13
disease-free survival (13) 13
radiotherapy (13) 13
stem-cell transplantation (13) 13
therapy (13) 13
young adult (13) 13
abridged index medicus (12) 12
life sciences (12) 12
patients (12) 12
research (12) 12
antineoplastic combined chemotherapy protocols - adverse effects (11) 11
childhood (11) 11
clinical trials (11) 11
high-risk neuroblastoma (11) 11
survival (11) 11
survival analysis (11) 11
transplantation (11) 11
busulfan - administration & dosage (10) 10
gene amplification (10) 10
high-dose chemotherapy (10) 10
metastatic neuroblastoma (10) 10
busulfan (9) 9
france (9) 9
immunotherapy (9) 9
induction chemotherapy (9) 9
metastases (9) 9
randomized-trial (9) 9
stage 4 neuroblastoma (9) 9
abstracts (8) 8
antineoplastic agents - therapeutic use (8) 8
cell line, tumor (8) 8
childrens oncology group (8) 8
hematopoietic stem cell transplantation (8) 8
medulloblastoma (8) 8
metastasis (8) 8
mycn (8) 8
neuroblastoma - diagnosis (8) 8
neuroblastoma - secondary (8) 8
proportional hazards models (8) 8
risk (8) 8
risk-factors (8) 8
vincristine - administration & dosage (8) 8
age factors (7) 7
bone marrow (7) 7
brain neoplasms - therapy (7) 7
brain-tumors (7) 7
care and treatment (7) 7
doxorubicin - administration & dosage (7) 7
epidemiology (7) 7
health aspects (7) 7
neoplasm recurrence, local (7) 7
neuroblastoma - metabolism (7) 7
pharmacokinetics (7) 7
prospective studies (7) 7
radiology, nuclear medicine & medical imaging (7) 7
stem cells (7) 7
analysis (6) 6
antineoplastic agents - adverse effects (6) 6
antineoplastic combined chemotherapy protocols - administration & dosage (6) 6
childhood-cancer (6) 6
cohort studies (6) 6
comparative genomic hybridization (6) 6
cyclophosphamide - administration & dosage (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Rigaud, Charlotte and Barkaoui, Mohamed A and Thomas, Caroline and Bertrand, Yves and Lambilliotte, Anne and Miron, Jean and Aladjidi, Nathalie and Plat, Geneviève and Jeziorski, Eric and Galambrun, Claire and Mansuy, Ludovic and Lutz, Patrick and Deville, Anne and Armari‐Alla, Corinne and Reguerre, Yves and Fraitag, Sylvie and Coulomb, Aurore and Gandemer, Virginie and Leboulanger, Nicolas and Moshous, Despina and Hoang‐Xuan, Khe and Tazi, Abdellatif and Heritier, Sébastien and Emile, Jean‐François and Donadieu, Jean and Kebaili, Kamila and Brugières, Laurence and Mazingue, Françoise and Pacquement, Hélène and Mary, Pierre and Jouve, Luc and Journé, Alexandre and Glorion, Christophe and Coze, Carole and Zerah, Michel and Leverger, Guy and Chastagner, Pascal and Moine, Philippe and Minckes, Odile and Lutun, Anne and Piguet, Christophe and Blouin, Pascale and Stephan, Louis and Pellier, Isabelle and Millot, Fréderic and Kanold, Justyna and Beaussant, Cohen and Lescoeur, Brigitte and Brousse, Nicole and Haroche, Julien and Genereau, Thierry and Munzer, Martine and Bugnet, Emmanuelle and Couillault, Gerard and Neven, Bénédicte and Lepointe, Ducou and Polak, Michel and Rybojad, Michel and Bodemer, Christine and Debray, Dominique and Devoldere, Catherine and Li‐Thiao‐Te, Valerie and Gourmel, Antoine and Pautard, Brigitte and Proust, Stephanie and Brasme, Francois and Rialland, Xavier and Plouvier, Emmanuel and Micheau, Magui and Perel, Yves and Verite, Cecile and Ducassou, Stephane and Carausu, Liana and Deparis, Marianna and Bodet, Damien and Dore, Eric and Demeocq, Francois and Briandet, Claire and Plantaz, Dominique and Pagnier, Anne and Adjaoud, Dalila and Nelken, Brigitte and Oudot, Caroline and Berard, Perrine and Dony, Arthur and Philippe, Noel and Gentet, Claude and Rome, Angelique and Herrmann, Iris and Michel, Gerard and Sirvent, Nicolas and Tichit, Renaud and Schmitt, Claudine and Sommelet, Danielle and Mechineau, Francoise and Bellmann, Francoise and Poiree, Maryline and Soler, Christine and Fasola, Sylvie and Auvrignon, Anne and ...
British Journal of Haematology, ISSN 0007-1048, 09/2016, Volume 174, Issue 6, pp. 887 - 898
Journal Article
Journal Article
Pediatric Blood & Cancer, ISSN 1545-5009, 06/2014, Volume 61, Issue 6, pp. 1101 - 1103
We present three pediatric patients with BRAFV600E mutant high-grade gliomas treated by vemurafenib on a nominative authorization level at our institution. One... 
pharmacokinetics | vemurafenib | BRAF | anaplastic ganglioglioma | mutations | pediatric brain tumors | Vemurafenib | Pharmacokinetics | Anaplastic ganglioglioma | Pediatric brain tumors | BRAF mutations | MELANOMA | ONCOLOGY | METASTASES | PEDIATRICS | HEMATOLOGY | Proto-Oncogene Proteins B-raf - physiology | Humans | Male | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Mutation, Missense | Protein Kinase Inhibitors - adverse effects | Bevacizumab | Cancer Vaccines - therapeutic use | Immunotherapy | Fatal Outcome | Camptothecin - administration & dosage | Thalamus | Antineoplastic Agents - pharmacokinetics | Ganglioglioma - surgery | Neoplasm Proteins - genetics | Child | Camptothecin - analogs & derivatives | Protein Kinase Inhibitors - pharmacokinetics | Ganglioglioma - drug therapy | Dacarbazine - administration & dosage | Ganglioglioma - radiotherapy | Combined Modality Therapy | Brain Neoplasms - drug therapy | Sulfonamides - pharmacokinetics | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Indoles - adverse effects | Indoles - therapeutic use | Neoplasm Proteins - physiology | Drug Evaluation | Salvage Therapy | Infant | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Agents - adverse effects | Astrocytoma - drug therapy | Dacarbazine - analogs & derivatives | Doxorubicin - analogs & derivatives | Ganglioglioma - enzymology | Astrocytoma - enzymology | Doxorubicin - administration & dosage | Brain Neoplasms - enzymology | Treatment Outcome | Cranial Irradiation | Polyethylene Glycols - administration & dosage | Point Mutation | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Sulfonamides - adverse effects | Indoles - pharmacokinetics | Pediatrics | Children | Gliomas | Health aspects | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9823, pp. 1301 - 1309
Journal Article
Pediatric Blood & Cancer, ISSN 1545-5009, 06/2014, Volume 61, Issue 6, pp. 977 - 981
BackgroundTo evaluate long-term survival of the first cohort of stage-4 neuroblastoma patients treated with the N7 induction chemotherapy, surgery of the... 
Busulphan–Melphalan | neuroblastoma | high‐dose chemotherapy | Busulphan-Melphalan | High-dose chemotherapy | Neuroblastoma | STAGE-4 NEUROBLASTOMA | BONE-MARROW-TRANSPLANTATION | 13-CIS-RETINOIC ACID | RANDOMIZED-TRIAL | ONCOLOGY | PEDIATRICS | HIGH-RISK NEUROBLASTOMA | STEM-CELL TRANSPLANTATION | OF-PEDIATRIC-ONCOLOGY | MULTIVARIATE-ANALYSIS | CHILDREN OLDER | HEMATOLOGY | high-dose chemotherapy | AGE | Myeloablative Agonists - therapeutic use | Follow-Up Studies | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Infant | Transplantation, Autologous | Consolidation Chemotherapy | Genes, myc | Busulfan - administration & dosage | Neuroblastoma - secondary | Child | Abdominal Neoplasms - drug therapy | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Treatment Outcome | Combined Modality Therapy | Remission Induction | Abdominal Neoplasms - surgery | Thoracic Neoplasms - surgery | Hepatic Veno-Occlusive Disease - chemically induced | Disease-Free Survival | Melphalan - administration & dosage | Gene Amplification | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neuroblastoma - drug therapy | Neuroblastoma - surgery | Thoracic Neoplasms - drug therapy | Transplantation Conditioning | Stem cells | Melphalan | Busulfan | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 4, pp. 500 - 514
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2011, Volume 29, Issue 4, pp. 449 - 455
Journal Article
Nature, ISSN 0028-0836, 10/2008, Volume 455, Issue 7215, pp. 967 - 970
Journal Article
Pediatric Blood & Cancer, ISSN 1545-5009, 04/2019, Volume 66, Issue 4, pp. e27556 - n/a
Given the biological and clinical heterogeneity of neuroblastoma, risk stratification is vital to determining appropriate treatment. Historically, most... 
neuroblastoma | risk stratification | high‐risk | biomarkers | high-risk | Heterogeneity | Population (statistical) | Historical account | Risk | Statistical methods | Neuroblastoma | Patients
Journal Article